Physician profile
Alan Plotner
NPI 1114983004
$11,905.52
in general payments reported to CMS, 2019-2025
42 companies · $3,182 in 2025
The $3,182 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $329 · 2021: $790 · 2022: $1,911 · 2023: $1,774 · 2024: $2,955 · 2025: $3,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,856 · Education: $54.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,855.94 |
| Education | $54.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,813.85 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,413.44 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Boston Scientific Corporation | $1,354.15 | 2021-2025 | Exalt Model D |
| Janssen Biotech, INC. | $806.33 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $683.02 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $573.10 | 2019-2025 | |
| Celgene Corporation | $500.86 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $453.94 | 2021-2025 | |
| Genzyme Corporation | $325.93 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $256.70 | 2019-2024 | Linzess |
| Qol Medical, LLC | $256.49 | 2020-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $243.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $222.41 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $207.21 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $200.33 | 2022-2025 | Dupixent |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $145.04 | 2019-2025 | Linx Reflux Management System |
| Enterra Medical, INC. | $142.18 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $131.87 | 2022-2024 | Zeposia |
| Olympus America INC. | $112.77 | 2019 | |
| Ardelyx, INC. | $106.01 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $101.11 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $96.64 | 2019-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $95.12 | 2025 | Zenpep, Vowst |
| Romark Laboratories, Lc | $89.73 | 2020 | |
| Celltrion USA INC. | $54.74 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $52.96 | 2021-2023 | |
| Erbe USA INC | $50.00 | 2024 | |
| Endo Pharmaceuticals INC. | $48.87 | 2019-2021 | |
| Novo Nordisk INC | $43.83 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $39.08 | 2019-2023 | Injectafer |
| Covidien Lp | $33.30 | 2019 | |
| Intercept Pharmaceuticals, INC. | $32.74 | 2023-2024 | Ocaliva |
| Pharmacosmos Therapeutics INC. | $31.30 | 2023 | Monoferric |
| Fresenius Kabi USA, LLC | $26.70 | 2023 | Idacio |
| Digestive Care, INC. | $25.55 | 2022 | |
| Allergan, INC. | $24.69 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.02 | 2025 | Ultomiris |
| Vivus LLC | $18.89 | 2024 | Qsymia |
| Medtronic, INC. | $18.24 | 2023 | Gi Genius |
| Capsovision, INC. | $17.93 | 2024 | Capsocam Plus |
| Organon LLC | $15.58 | 2022 | |
| Alfasigma USA, INC. | $15.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Plotner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.